The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL).
 
Igor Puzanov
No Relationships to Disclose
 
Reinhard Dummer
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche
 
Jacob Schachter
Honoraria - Bristol-Myers Squibb; MSD
Consulting or Advisory Role - MSD
Patents, Royalties, Other Intellectual Property - Leica Biosystems
 
Anna C. Pavlick
No Relationships to Disclose
 
Rene Gonzalez
Honoraria - Amgen; Bristol-Myers Squibb; Castle Biosciences; GlaxoSmithKline; Roche/Genentech
Consulting or Advisory Role - Piramal Life Science; Roche Pharma AG
Research Funding - Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Roche Pharma AG (Inst)
 
Paolo Antonio Ascierto
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Roche/Genentech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb (Inst); Roche/Genentech (Inst); Ventana Medical Systems (Inst)
 
Kim Allyson Margolin
Consulting or Advisory Role - Nektar; NeoStem; Oncosec; Prothena
 
Omid Hamid
Consulting or Advisory Role - Merck
Research Funding - Merck (Inst)
 
Sanjiv S. Agarwala
No Relationships to Disclose
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck
 
Jochen Utikal
Consulting or Advisory Role - GlaxoSmithKline; Roche Pharma AG
Speakers' Bureau - GlaxoSmithKline; Roche Pharma AG
Travel, Accommodations, Expenses - Roche Pharma AG
 
Michal Lotem
No Relationships to Disclose
 
Antoni Ribas
Stock and Other Ownership Interests - Compugen; Kite, a Gilead company
Consulting or Advisory Role - Amgen; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Merck Sharp & Dohme (Inst)
 
Peter Mohr
Honoraria - GlaxoSmithKline; Merck; Merck Sharp & Dohme; MSD; Roche Pharma AG
Consulting or Advisory Role - GlaxoSmithKline; Merck; Merck Sharp & Dohme; MSD; Roche Pharma AG
Research Funding - Merck; Merck Sharp & Dohme; MSD; Roche Pharma AG
Travel, Accommodations, Expenses - Merck; Merck Sharp & Dohme; MSD; Roche Pharma AG
 
Charlotte M. Roach
Employment - DAKO
 
Marisa Dolled-Filhart
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Xiaoyun Nicole Li
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Scot Ebbinghaus
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Soonmo Peter Kang
Employment - Merck
Stock and Other Ownership Interests - Agenus; Celgene; Celldex; Endocyte; Macrogenics; Merck; Pharmacyclics
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Merck
 
Adil Daud
Stock and Other Ownership Interests - Oncosec
Consulting or Advisory Role - GlaxoSmithKline; Merck; Oncosec
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck/Schering Plough (Inst); oncosec (Inst); Pfizer (Inst)